GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (MIL:1BMY) » Definitions » COGS-to-Revenue

Bristol-Myers Squibb Co (MIL:1BMY) COGS-to-Revenue : 0.25 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bristol-Myers Squibb Co COGS-to-Revenue?

Bristol-Myers Squibb Co's Cost of Goods Sold for the three months ended in Sep. 2024 was €2,664 Mil. Its Revenue for the three months ended in Sep. 2024 was €10,715 Mil.

Bristol-Myers Squibb Co's COGS to Revenue for the three months ended in Sep. 2024 was 0.25.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Bristol-Myers Squibb Co's Gross Margin % for the three months ended in Sep. 2024 was 75.13%.


Bristol-Myers Squibb Co COGS-to-Revenue Historical Data

The historical data trend for Bristol-Myers Squibb Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co COGS-to-Revenue Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.28 0.21 0.22 0.24

Bristol-Myers Squibb Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.23 0.24 0.25 0.27 0.25

Bristol-Myers Squibb Co COGS-to-Revenue Calculation

Bristol-Myers Squibb Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=9805.481 / 41270.502
=0.24

Bristol-Myers Squibb Co's COGS to Revenue for the quarter that ended in Sep. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=2664.257 / 10714.692
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bristol-Myers Squibb Co  (MIL:1BMY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Bristol-Myers Squibb Co's Gross Margin % for the three months ended in Sep. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 2664.257 / 10714.692
=75.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Bristol-Myers Squibb Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Address
Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Co Headlines

No Headlines